Alto Neuroscience's (ANRO) Outperform Rating Reiterated at William Blair

Alto Neuroscience (NYSE:ANRO - Get Free Report)'s stock had its "outperform" rating reissued by equities researchers at William Blair in a research report issued on Friday,RTT News reports. William Blair also issued estimates for Alto Neuroscience's Q1 2026 earnings at ($0.53) EPS, Q2 2026 earnings at ($0.53) EPS, Q3 2026 earnings at ($0.43) EPS and Q4 2026 earnings at ($0.43) EPS.

Alto Neuroscience Trading Down 3.4 %

NYSE ANRO traded down $0.09 during trading on Friday, hitting $2.56. 218,997 shares of the company's stock traded hands, compared to its average volume of 360,312. The stock has a fifty day moving average of $3.56 and a two-hundred day moving average of $5.90. Alto Neuroscience has a 12-month low of $2.58 and a 12-month high of $18.35. The firm has a market cap of $69.04 million and a P/E ratio of -1.01. The company has a debt-to-equity ratio of 0.05, a current ratio of 13.10 and a quick ratio of 13.09.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last issued its earnings results on Thursday, March 20th. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.09. As a group, sell-side analysts expect that Alto Neuroscience will post -2.54 EPS for the current year.

Institutional Investors Weigh In On Alto Neuroscience

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wells Fargo & Company MN increased its position in shares of Alto Neuroscience by 40.0% in the fourth quarter. Wells Fargo & Company MN now owns 10,989 shares of the company's stock valued at $46,000 after acquiring an additional 3,139 shares during the period. BNP Paribas Financial Markets grew its stake in shares of Alto Neuroscience by 619.2% in the third quarter. BNP Paribas Financial Markets now owns 4,315 shares of the company's stock worth $49,000 after purchasing an additional 3,715 shares during the last quarter. Deutsche Bank AG increased its holdings in Alto Neuroscience by 31.3% during the 4th quarter. Deutsche Bank AG now owns 15,210 shares of the company's stock valued at $64,000 after purchasing an additional 3,629 shares during the period. Skandinaviska Enskilda Banken AB publ bought a new position in Alto Neuroscience during the 4th quarter valued at approximately $74,000. Finally, Jane Street Group LLC lifted its holdings in Alto Neuroscience by 72.0% in the 4th quarter. Jane Street Group LLC now owns 18,600 shares of the company's stock worth $79,000 after buying an additional 7,783 shares during the period.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.